Pfizer said the patient, a young boy who was treated earlier last year, had died suddenly. The company is working with trial researchers to investigate further.

Crafting a professional career doesn’t always go according to design. Despite carefully laid plans, twists and turns arise and unexpected opportunities unfold. That’s certainly the case with Leen ...

We are absolutely thrilled to welcome Jonathan into this critical leadership role for Sapient,” said Mo Jain, MD, PhD, Founder and CEO of Sapient. “He is a rare talent possessing both deep scientific ...

The $200 million round is the latest evidence that surging interest in autoimmune disease cell therapies could expand to include developers of bispecific antibodies, too.

Weeks after a safety setback derailed its lead candidate, the company has treated the first participant in an early trial of its heart disease treatment Verve-102.

The honor is underscored by recent news highlighting the strength of the PumasAI team and its technology for the pharmaceutical industry, including: A focus on leading industry workshops to further ...

A 12-year-old boy in the Washington, D.C., area is set become the first patient treated with Lyfgenia since its U.S. approval last December.

One of the most significant impacts, however, is the new FDORA diversity action plan requirement. Diversity action plans are now a requirement for clinical trial sponsors, including Phase III, pivotal ...

Multimodal Entity Registration – Sapio’s enhanced molecular biology tools are integrated with small molecule research, enabling scientists to enhance their understanding and development of novel ...

One analyst thinks the collaboration “bodes well” for Gossamer, which has had trouble convincing investors its drug seralutinib can compete on the market.

The company, BridgeBio Oncology Therapeutics, has one drug in the clinic and hopes to soon advance two other candidates.

The British drugmaker, which has made genetic medicine a larger priority of late, added $140 million to a deal to develop up to 10 gene and cell therapies.